<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108519</url>
  </required_header>
  <id_info>
    <org_study_id>PA18-1070</org_study_id>
    <secondary_id>NCI-2021-06311</secondary_id>
    <nct_id>NCT05108519</nct_id>
  </id_info>
  <brief_title>Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies</brief_title>
  <official_title>A Prospective Study Evaluating Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study collects information about complications and clinical response in cancer patients&#xD;
      treated with anti-VEGF-related therapies. This study aims to observe side effects that may&#xD;
      happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This&#xD;
      may help doctors learn if there are any relationships between these side effects and how the&#xD;
      disease may respond to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To explore the incidence of clinical complications associated with anti-VEGF-related&#xD;
      therapies in cancer patients treated at Emory University and the University of Texas M.D.&#xD;
      Anderson Cancer Center (MDACC).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To explore the correlation of clinical response rates to a novel blood pressure scoring&#xD;
      system in cancer patients treated with anti-VEGF-related therapies.&#xD;
&#xD;
      II. To explore the correlation of objective response to each toxicity grade 3 or higher in&#xD;
      cancer patients treated with anti-VEGF-related therapies.&#xD;
&#xD;
      III. To investigate the validity of a novel multi-parameter-based blood pressure scoring&#xD;
      system and to determine if the new scoring method is concordant with the current Common&#xD;
      Terminology Criteria for Adverse Events (CTCAE) method.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients' medical records are reviewed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2019</start_date>
  <completion_date type="Anticipated">May 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade 3+ adverse events (AE) at least possibly related to anti-VEGF-related treatment (overall and each type separately)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>For each toxicity, will estimate the odds ratio, associated 95% confidence interval and p-value.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Observational (medical records review)</arm_group_label>
    <description>Patients' medical records are reviewed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Medical records are reviewed</description>
    <arm_group_label>Observational (medical records review)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving any anti-VEGF-related regimen&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be able to understand and be willing to sign a written informed consent&#xD;
             document&#xD;
&#xD;
          -  Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination&#xD;
             therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas L Palaskas</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas L. Palaskas</last_name>
      <phone>713-563-3532</phone>
      <email>nlpalaskas@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Nicolas L. Palaskas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

